CA2967112C - Quinoline carboxamides for use in the treatment of leukemia - Google Patents

Quinoline carboxamides for use in the treatment of leukemia Download PDF

Info

Publication number
CA2967112C
CA2967112C CA2967112A CA2967112A CA2967112C CA 2967112 C CA2967112 C CA 2967112C CA 2967112 A CA2967112 A CA 2967112A CA 2967112 A CA2967112 A CA 2967112A CA 2967112 C CA2967112 C CA 2967112C
Authority
CA
Canada
Prior art keywords
leukemia
pharmaceutically acceptable
compound
acceptable salt
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2967112A
Other languages
English (en)
French (fr)
Other versions
CA2967112A1 (en
Inventor
Helena ERIKSSON
Leif Svensson
Marie Torngren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Active Biotech AB
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Publication of CA2967112A1 publication Critical patent/CA2967112A1/en
Application granted granted Critical
Publication of CA2967112C publication Critical patent/CA2967112C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2967112A 2014-11-19 2015-11-05 Quinoline carboxamides for use in the treatment of leukemia Active CA2967112C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193776.3 2014-11-19
EP14193776 2014-11-19
PCT/EP2015/075769 WO2016078921A1 (en) 2014-11-19 2015-11-05 Quinoline carboxamides for use in the treatment of leukemia

Publications (2)

Publication Number Publication Date
CA2967112A1 CA2967112A1 (en) 2016-05-26
CA2967112C true CA2967112C (en) 2023-05-16

Family

ID=51951635

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2967112A Active CA2967112C (en) 2014-11-19 2015-11-05 Quinoline carboxamides for use in the treatment of leukemia

Country Status (15)

Country Link
US (1) US10300053B2 (enExample)
EP (1) EP3180005B1 (enExample)
JP (1) JP6715833B2 (enExample)
KR (1) KR102525805B1 (enExample)
CN (1) CN107072989B (enExample)
AU (1) AU2015348778B2 (enExample)
BR (1) BR112017009854B1 (enExample)
CA (1) CA2967112C (enExample)
EA (1) EA031643B1 (enExample)
ES (1) ES2663836T3 (enExample)
IL (1) IL252174B (enExample)
MX (1) MX379401B (enExample)
NZ (1) NZ732704A (enExample)
PL (1) PL3180005T3 (enExample)
WO (1) WO2016078921A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3032708T3 (en) 2020-03-03 2025-07-23 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
MX2023000903A (es) 2020-07-23 2023-04-20 Univ Erasmus Med Ct Rotterdam Proteinas s100 como nuevos objetivos terapeuticos en neoplasias mieloproliferativas.
CN116887844A (zh) * 2021-01-18 2023-10-13 活跃生物技术有限公司 用于治疗骨髓增生异常综合征的他喹莫德或其药学上可接受的盐
KR20230133317A (ko) 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
AU2022281056A1 (en) 2021-05-25 2023-11-30 Active Biotech Ab A plurality of tasquinimod particles and use thereof
CA3221689A1 (en) 2021-07-02 2023-01-05 Hans Wannman A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
WO2015095833A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers

Also Published As

Publication number Publication date
MX2017006110A (es) 2017-07-27
MX379401B (es) 2025-03-11
KR20170083121A (ko) 2017-07-17
JP2017534652A (ja) 2017-11-24
CA2967112A1 (en) 2016-05-26
IL252174A0 (en) 2017-07-31
BR112017009854B1 (pt) 2022-08-23
WO2016078921A1 (en) 2016-05-26
IL252174B (en) 2021-02-28
AU2015348778A1 (en) 2017-06-29
EA201791099A1 (ru) 2017-10-31
CN107072989A (zh) 2017-08-18
EP3180005A1 (en) 2017-06-21
US20170319568A1 (en) 2017-11-09
PL3180005T3 (pl) 2018-06-29
AU2015348778B2 (en) 2020-12-24
EA031643B1 (ru) 2019-01-31
US10300053B2 (en) 2019-05-28
BR112017009854A2 (pt) 2018-01-16
ES2663836T3 (es) 2018-04-17
JP6715833B2 (ja) 2020-07-01
NZ732704A (en) 2022-01-28
EP3180005B1 (en) 2017-12-27
CN107072989B (zh) 2020-07-03
KR102525805B1 (ko) 2023-04-25

Similar Documents

Publication Publication Date Title
CA2967112C (en) Quinoline carboxamides for use in the treatment of leukemia
US10314836B2 (en) Quinoline carboxamides for use in the treatment of multiple myeloma
CN104436194B (zh) 具有协同增效作用的抗癌组合物
TW202019409A (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或bcl-2抑制劑與chop聯合用藥的協同抗腫瘤作用
JP2011503063A5 (enExample)
JP2017534652A5 (enExample)
HK1237658B (en) Quinoline carboxamides for use in the treatment of leukemia
HK1237658A1 (en) Quinoline carboxamides for use in the treatment of leukemia
EP3880207A1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
EP2902028A1 (en) Drug composition for treating tumors and application thereof
HK1226643A1 (en) Quinoline carboxamides for use in the treatment of multiple myeloma
HK1226643B (en) Quinoline carboxamides for use in the treatment of multiple myeloma
CN112535686B (zh) 激酶抑制剂的新用途
BR112017004947B1 (pt) Uso de um composto ou sal farmaceuticamente aceitável
TW202002970A (zh) 用於預防或治療癌症之組合物,其包含血管阻斷劑及紫杉烷化合物
WO2025006886A9 (en) Quinoline carboxamides for use in the treatment of mpn
JP2005041801A (ja) 細胞移植療法後の予後改善剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

EEER Examination request

Effective date: 20201015

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241028

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241028